Grindeks to supply oxytocin for PATH's project
This article was originally published in Scrip
Latvia's Grindeks has entered into a joint project with Instituto Biologico Argentino (BIOL) of Argentina to supply oxytocin for Uniject, BIOL's disposable prefilled syringe. The project is being run by the Program for Appropriate Technology in Health (PATH), an international non-profit organisation, which assists in providing health technologies to developing countries and poor regions. BIOL, a private company that specialises in biological products, has provided the device to PATH since 2004.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.